SAN MATEO, Calif., June 22, 2020 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) today announced the results of two preclinical studies presented at the American Association for Cancer Research (AACR) Virtual Meeting II.  These studies further demonstrate the mechanism of action of Rakuten Medical’s Illuminox™ technology platform with its antibody-IRDye^® 700DX conjugate and how this unique technology induces tumor cells and enhances the adaptive immune response. Read More